Global Polymyalgia Rheumatica Market Report 2025: Market Opportunities & Challenges Outlook

 Built for executives and teams involved in growth planning, this research offers a data-driven view of the polymyalgia rheumatica industry’s direction and competitive environment.

 

 How Big Is The Polymyalgia Rheumatica Market In 2025?
 The polymyalgia rheumatica market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.36 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising awareness among healthcare practitioners, rising use of corticosteroids, growth in specialty clinics, the introduction of biologic therapies, and rising healthcare budgets.
 
 The polymyalgia rheumatica market size is expected to see strong growth in the next few years. It will grow to $1.72 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to the growing adoption of biologics, expansion of precision medicine, accelerated drug approvals, broader reimbursements, and expansion of clinical trials. Major trends in the forecast period include the development of combination therapies, advancements in personalized medicine, the development of precision medicine, the integration of electronic health records, and advancements in biomarkers.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp
 
 What Are The Major Factors Driving The Polymyalgia Rheumatica Global Market Growth?
 The rise in demand for personalized medicine is expected to propel the growth of the polymyalgia rheumatica market going forward. Personalized medicine is medical treatment tailored to an individual’s genetic profile, lifestyle, and specific health conditions for more effective outcomes. The demand for personalized medicine is driven by advancements in genetic research, growing patient expectations for tailored treatments, and improvements in diagnostic technologies. Genetic research provided a deeper understanding of individual genetic variations, allowing for more customized treatments targeting specific genetic markers. Personalized medicine can help select drugs that are most likely effective based on the patient’s characteristics, leading to a more effective and safer treatment plan. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the rise of personalized medicine is driving the growth of the polymyalgia rheumatica market.
 
 Polymyalgia Rheumatica Market Report Segmentation Analysis
 The polymyalgia rheumaticamarket covered in this report is segmented — 
 
 1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics
 2) By Route Of Administration: Oral; Intravenous; Subcutaneous
 3) By Patient Type: Adult; Geriatric; Periatric
 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
 
 Subsegments:
 1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
 2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib
 3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine
 4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors
 
 Emerging Trends And Strategic Opportunities In The Polymyalgia Rheumatica Market
 Major companies operating in the polymyalgia rheumatica market are focusing on developing advanced drugs, such as interleukin-6 (IL-6) receptor blockers, to provide more targeted and effective treatment options. Interleukin-6 (IL-6) receptor blockers are biological drugs that inhibit IL-6, a key pro-inflammatory cytokine in autoimmune diseases. By blocking IL-6, these treatments reduce inflammation and improve symptoms, enhancing the quality of life for PMR patients. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare company, announced the Food and Drug Administration (FDA) approved Kevzara (sarilumab) for treating polymyalgia rheumatica (PMR) in adults who haven’t responded well to corticosteroids or can’t tolerate tapering off them. Kevzara, the first and only biologic approved for this condition, works by inhibiting IL-6-mediated signaling. The approval was based on a study where 28.3% of patients on sarilumab achieved sustained remission at week 52, compared to 10.3% on placebo2. Kevzara is administered via subcutaneous injection once every two weeks and is also approved for treating moderately to severely active rheumatoid arthritis. Sanofi’s stock (SNY) is currently priced at $54.13 on the NASDAQ.
 
 What Are The Top Players Operating In The Polymyalgia Rheumatica Market?
 Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital 
 
 View the full polymyalgia rheumatica market report here:
 https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report
 
 Which Region Holds The Largest Market Share In The Polymyalgia Rheumatica Market?
 Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company